ACM
Alethea Capital Management’s Avidity Biosciences RNA Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $12.2M | Buy |
428,624
+6,900
| +2% | +$196K | 9.21% | 3 |
|
|
2025
Q1 | $12.4M | Buy |
421,724
+853
| +0.2% | +$25.2K | 9.29% | 3 |
|
|
2024
Q4 | $12.2M | Sell |
420,871
-6,583
| -2% | -$191K | 10.48% | 3 |
|
|
2024
Q3 | $19.6M | Sell |
427,454
-76,050
| -15% | -$3.49M | 14.18% | 3 |
|
|
2024
Q2 | $20.6M | Sell |
503,504
-257,193
| -34% | -$10.5M | 15.61% | 3 |
|
|
2024
Q1 | $19.4M | Sell |
760,697
-93,954
| -11% | -$2.4M | 15.77% | 3 |
|
|
2023
Q4 | $7.73M | Hold |
854,651
| – | – | 8.92% | 2 |
|
|
2023
Q3 | $5.45M | Buy |
854,651
+5,000
| +0.6% | +$31.9K | 6.7% | 2 |
|
|
2023
Q2 | $9.42M | Hold |
849,651
| – | – | 10.08% | 2 |
|
|
2023
Q1 | $13M | Buy |
849,651
+24,178
| +3% | +$371K | 13.77% | 2 |
|
|
2022
Q4 | $18.3M | Sell |
825,473
-10,000
| -1% | -$222K | 17.56% | 2 |
|
|
2022
Q3 | $13.6M | Hold |
835,473
| – | – | 17.24% | 2 |
|
|
2022
Q2 | $12.1M | Sell |
835,473
-54,484
| -6% | -$792K | 15.2% | 2 |
|
|
2022
Q1 | $16.4M | Buy |
889,957
+420
| +0% | +$7.76K | 14.87% | 2 |
|
|
2021
Q4 | $21.1M | Sell |
889,537
-18,030
| -2% | -$429K | 17.94% | 2 |
|
|
2021
Q3 | $22.4M | Sell |
907,567
-259,180
| -22% | -$6.38M | 19.68% | 2 |
|
|
2021
Q2 | $28.8M | Sell |
1,166,747
-219,117
| -16% | -$5.41M | 18.14% | 2 |
|
|
2021
Q1 | $30.2M | Sell |
1,385,864
-185,296
| -12% | -$4.04M | 18.44% | 2 |
|
|
2020
Q4 | $40.1M | Buy |
+1,571,160
| New | +$40.1M | 20.1% | 2 |
|